• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Latest Analyst Ratings for NuVasive

    5/31/23 8:09:10 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care
    Get the next $NUVA alert in real time by email

    Within the last quarter, NuVasive (NASDAQ:NUVA) has observed the following analyst ratings:

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 0 3 2 0 0
    Last 30D 0 0 1 0 0
    1M Ago 0 3 1 0 0
    2M Ago 0 0 0 0 0
    3M Ago 0 0 0 0 0

    According to 5 analyst offering 12-month price targets in the last 3 months, NuVasive has an average price target of $51.0 with a high of $58.00 and a low of $40.00.

    Below is a summary of how these 5 analysts rated NuVasive over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

    price target chart

    This current average has increased by 8.9% from the previous average price target of $46.83.

    Stay up to date on NuVasive analyst ratings.

    If you are interested in following small-cap stock news and performance you can start by tracking it here.

    What Are Analyst Ratings?

    Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

    Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

    Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $NUVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVA

    DatePrice TargetRatingAnalyst
    2/10/2023$57.72Overweight → Equal Weight
    Wells Fargo
    2/10/2023$63.00 → $52.00Buy → Neutral
    Citigroup
    2/10/2023$51.00 → $52.50Buy → Hold
    Truist
    1/6/2023Buy → Hold
    Needham
    10/18/2022$53.00Overweight
    Barclays
    10/12/2022$45.00Hold
    Jefferies
    4/13/2022$60.00 → $65.00Buy
    Truist
    3/28/2022$58.00Overweight
    Wells Fargo
    More analyst ratings

    $NUVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wolterman Dan

    4 - NUVASIVE INC (0001142596) (Issuer)

    9/5/23 5:06:55 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Raimundo Amy Belt

    4 - NUVASIVE INC (0001142596) (Issuer)

    9/5/23 5:04:52 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Norwalk Leslie V returned 3,095 shares to the company, closing all direct ownership in the company

    4 - NUVASIVE INC (0001142596) (Issuer)

    9/5/23 4:55:04 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting

    SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle.  "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi

    8/30/23 7:00:00 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600

    NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond

    8/28/23 5:41:00 PM ET
    $GMED
    $GSHD
    $JXN
    Medical/Dental Instruments
    Health Care
    Specialty Insurers
    Finance

    NuVasive Announces Second Quarter 2023 Financial Results

    –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

    8/2/23 4:05:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NuVasive downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72

    2/10/23 8:01:18 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    NuVasive downgraded by Citigroup with a new price target

    Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously

    2/10/23 7:45:41 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    NuVasive downgraded by Truist with a new price target

    Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously

    2/10/23 7:45:03 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    SEC Filings

    View All

    SEC Form 15-12G filed by NuVasive Inc.

    15-12G - NUVASIVE INC (0001142596) (Filer)

    9/11/23 4:46:57 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NuVasive Inc.

    EFFECT - NUVASIVE INC (0001142596) (Filer)

    9/8/23 12:15:09 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NuVasive Inc.

    EFFECT - NUVASIVE INC (0001142596) (Filer)

    9/8/23 12:15:14 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Financials

    Live finance-specific insights

    View All

    NuVasive Announces Second Quarter 2023 Financial Results

    –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

    8/2/23 4:05:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results

    SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle

    7/24/23 7:00:00 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    NuVasive Announces First Quarter 2023 Financial Results

    –Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a

    5/10/23 4:05:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Leadership Updates

    Live Leadership Updates

    View All

    BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

    SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

    9/7/22 8:30:00 AM ET
    $AFIB
    $AVGR
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Blue Spark Technologies Announces Appointment of John DeFord, Ph.D. to its Board of Directors

    The new board member will provide extensive expertise to expand the TempTraq® remote patient monitoring platform Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord's appointment, effective April 13th, 2022, brings the number of board members to five. "This is really an inflection point for the company and it's an exciting time to be involved. I look forward to helping mold the future of their technology," said Dr. DeFord. "I'm particularly excited to see the technology come together that will make an impact in patient's lives." "We are proud to welcome John to

    5/2/22 7:00:00 AM ET
    $NDSN
    $NUVA
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer

    SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022. Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company

    1/31/22 4:10:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

    SC 13G/A - NUVASIVE INC (0001142596) (Subject)

    9/11/23 1:33:44 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by NuVasive Inc.

    SC 13G - NUVASIVE INC (0001142596) (Subject)

    2/13/23 3:58:05 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

    SC 13G/A - NUVASIVE INC (0001142596) (Subject)

    12/6/22 10:35:04 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care